Featured Research

from universities, journals, and other organizations

Protecting brains of very preterm infants

Date:
August 26, 2014
Source:
Université de Genève
Summary:
Premature babies are far more at risk than infants born at term of developing brain damage resulting in neurodevelopmental delay that may persist throughout their lives. A team of specialists in infant brain imaging has demonstrated that administering three doses of erythropoietin may help.

Premature babies are far more at risk than infants born at term of developing brain damage resulting in neurodevelopmental delay that may persist throughout their lives. A team of specialists in infant brain imaging from the Faculty of Medicine at the University of Geneva (UNIGE) and the University Hospital of Geneva (HUG) has demonstrated the following: administering three doses of erythropoietin -- a hormone that stimulates the formation of red blood cells -- immediately after birth significantly reduces brain damage in babies. The results are available in more detail in the Journal of American Medical Association (JAMA).

Nearly 400,000 children are born in Europe every year before the 32nd week of pregnancy (and 2.6 million worldwide, according to the World Health Organisation), including around 80 at HUG. There are numerous health implications for children who are born so prematurely, including brain damage and incomplete maturation of the brain, especially the white matter responsible for propagating information in the nervous system. New imaging techniques, including magnetic resonance imaging (MRI) -- a non-invasive method with no radiation exposure -- make it possible to identify brain damage at an early stage that could have long-term consequences on a child's development: including motor and cognitive problems, attention and learning difficulties leading to loss of human capital .

EPO: a well-known hormone

Synthetic erythropoietin (EPO) -- whose doping effects amongst athletes are well-known -- is a treatment commonly used to prevent anemia; it is also used in preterm infants, as it reduces the need for blood transfusions. A number of recent studies have shown that the same hormone also has a neuroprotective effect. The Geneva team, led by Petra Susan Hüppi, professor in the Faculty of Medicine at UNIGE and head of the Division of Development and Growth in the Department of Paediatrics at HUG, set out to verify the impact of EPO on premature babies brain. They reviewed the MRI scans of 165 children, half of whom had received three doses of EPO within two days of birth. "We found that the brains of the children who had received the treatment had much less damage than those in the control group, who had been given a placebo," explains Russia Ha-Vinh Leuchter, co-author of the study: "This is the first time that the beneficial effect of the EPO hormone on the brains of premature babies has been shown."

The first chapter in a nationwide study

The research is led by Geneva and forms part of an extensive Swiss study carried out in cooperation with the University of Zurich, covering 495 children born in Switzerland between 2005 and 2012. The second -- and main -- part of the work will focus on the neurocognitive development of these children, who will take part in various developmental tests at the age of two and five years. As professor Petra Hüppi explains: "State-of-the-art developmental testing as performed in our Swiss Developmental Pediatric units should confirm the effect that EPO treatment has on the neurodevelopmental disabilities that very premature babies often show during their infancy." The professor concludes: "If this does turn out to be the case, we will have taken an important step in preventing brain damage and its longterm consequences in premature babies." The main findings of the study, therefore, are yet to come.


Story Source:

The above story is based on materials provided by Université de Genève. Note: Materials may be edited for content and length.


Journal Reference:

  1. Russia Ha-Vinh Leuchter, Laura Gui, Antoine Poncet, Cornelia Hagmann, Gregory Anton Lodygensky, Ernst Martin, Brigitte Koller, Alexandra Darqué, Hans Ulrich Bucher, Petra Susan Hüppi. Association Between Early Administration of High-Dose Erythropoietin in Preterm Infants and Brain MRI Abnormality at Term-Equivalent Age. JAMA, 2014; 312 (8): 817 DOI: 10.1001/jama.2014.9645

Cite This Page:

Université de Genève. "Protecting brains of very preterm infants." ScienceDaily. ScienceDaily, 26 August 2014. <www.sciencedaily.com/releases/2014/08/140826205517.htm>.
Université de Genève. (2014, August 26). Protecting brains of very preterm infants. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2014/08/140826205517.htm
Université de Genève. "Protecting brains of very preterm infants." ScienceDaily. www.sciencedaily.com/releases/2014/08/140826205517.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins